Avant Proteins to exit SG as director cites inability to pay debts

The group declared it is unable to continue due to liabilities.

Avant Proteins Pte. Ltd. has declared that it is unable to continue its business due to its liabilities, according to a notice published in Singapore’s Government Gazette on 29 January.

In a statutory declaration made under the ‘Insolvency, Restructuring and Dissolution Act 2018’, director Chan Kai Yi Carrie said that the company “cannot, by reason of its liabilities, continue its business.”

The declaration was made on 26 January. Meetings of the company and its creditors have been scheduled for 13 February 2026.

Separately, Avant Proteins will transition its operations out of Singapore, the group said in a LinkedIn post.

The company established its Singapore presence in 2021 through a project with the A*STAR Bioprocessing Technology Institute at Biopolis and later operated a pilot facility in Woodlands.

If you've been wondering whether SBR could work for your company — yes, probably.

A lot of the companies we partner with started as readers. They'd been following our coverage for a while, saw their own customers and competitors in it, and eventually asked the obvious question: could we do something with you? The answer is usually yes. The shape of it depends on what you're trying to do.

The options are broader than most people assume — thought leadership articles, sponsored content, industry summits across Southeast Asia, regional awards programmes, podcasts, and media placements in print and digital. Some partners use one channel; most use a mix. We figure out the right combination by starting with your brief, not with our rate card.

So if the question has been on your mind, here's the easy way to ask it.

We'll tell you honestly whether we can help, and how. It's a better use of everyone's time.

Book a meeting

| Or download the media kit (PDF)

240,000 senior readers quarterly in print Top 1,700 Singapore companies reached

7 markets across Southeast Asia